We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00195286
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : September 25, 2009
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary:
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

Condition or disease Intervention/treatment Phase
Urinary Infections Drug: piperacillin/tazobactam Phase 4

Study Type : Observational
Actual Enrollment : 180 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
Study Start Date : June 2004
Primary Completion Date : July 2007
Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients treated at internal medicine units

Inclusion Criteria:

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria:

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00195286

Antequera (Málaga), Spain
Avila, Spain
Barcelona, Spain
Berga (Barcelona), Spain
Caceres, Spain
Castellón, Spain
Ciudad Real, Spain
Cuenca, Spain
Cádiz, Spain
Ferrol, Spain
Granada, Spain
Jaen, Spain
Las Palmas, Spain
Lorca (Murcia), Spain
Lugo, Spain
Lérida, Spain
Madrid, Spain
Osuna (Sevilla), Spain
Palma Mallorca, Spain
Pamplona, Spain
Pontevedra, Spain
Terrasa, Spain
Torrelavega, Spain
Valencia, Spain
Valladolid, Spain
Vitoria, Spain
Zaragoza, Spain
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00195286     History of Changes
Other Study ID Numbers: 101315
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: September 25, 2009
Last Verified: September 2009

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Urinary Infections

Additional relevant MeSH terms:
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Penicillanic Acid
Piperacillin, tazobactam drug combination
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action